Literature DB >> 11517221

Elevated function of blood clotting factor VIIa mutants that have enhanced affinity for membranes. Behavior in a diffusion-limited reaction.

G L Nelsestuen1, M Stone, M B Martinez, S B Harvey, D Foster, W Kisiel.   

Abstract

Blood clotting factor VIIa is involved in the first step of the blood coagulation cascade, as a membrane-associated enzyme in complex with tissue factor (TF). Factor VIIa is also an important therapeutic agent for hemophilia where its function may include TF-independent as well as TF-dependent mechanisms. This study compared the activity of wild type factor VIIa (WT-VIIa) with that of a mutant with elevated affinity for membrane (P10Q/Q32E, QE-VIIa). Phospholipid and cell-based assays showed the mutant to have up to 40-fold higher function than WT-VIIa in both TF-dependent and TF-independent reactions. Tissue factor-dependent reactions displayed the maximum enhancement when binding had reached equilibrium in competition with another TF-binding protein. In liposome-based assays, the association rate of WT-VIIa with TF occurred at a physical maximum and could not be improved by site-directed mutagenesis. A practical consequence was identical function of WT-VIIa and QE-VIIa in assays that depended entirely on assembly kinetics. Thus, factor VIIa mutants provided unique reagents for probing the mechanism of factor VIIa action. They may also offer superior agents for therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11517221     DOI: 10.1074/jbc.M104896200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  Long-term expression of canine FVIIa in hemophilic dogs.

Authors:  Paris Margaritis
Journal:  Thromb Res       Date:  2010-02-10       Impact factor: 3.944

2.  Disulfide locked variants of factor VIIa with a restricted beta-strand conformation have enhanced enzymatic activity.

Authors:  Henry R Maun; Charles Eigenbrot; Helga Raab; David Arnott; Lilian Phu; Sherron Bullens; Robert A Lazarus
Journal:  Protein Sci       Date:  2005-05       Impact factor: 6.725

3.  A soluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties.

Authors:  Xin Huang; Wei-Qun Ding; Joshua L Vaught; Roman F Wolf; James H Morrissey; Roger G Harrison; Stuart E Lind
Journal:  Blood       Date:  2005-09-29       Impact factor: 22.113

4.  Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo.

Authors:  Paris Margaritis; Elise Roy; Armida Faella; Harre D Downey; Lacramioara Ivanciu; Giulia Pavani; Shangzhen Zhou; Ralph M Bunte; Katherine A High
Journal:  Blood       Date:  2011-02-16       Impact factor: 22.113

5.  A recombinant adenovirus vector encoding the light chain of human coagulation factor VII and IgG1 Fc fragment to targeting tissue factor for colorectal cancer immunotherapy in the mouse model.

Authors:  Benqiang Rao; Yuanhong Gao; Qixu Zhou; Pei Xiao; Shuang Xia; Jingsheng Ma; Juan Luo; Tao Xiao; Shilian Le; Meijin Huang; Jianping Wang
Journal:  J Cancer Res Clin Oncol       Date:  2013-03-15       Impact factor: 4.553

6.  Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII.

Authors:  Paris Margaritis; Valder R Arruda; Majed Aljamali; Rodney M Camire; Alexander Schlachterman; Katherine A High
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

7.  Computational study of coagulation factor VIIa's affinity for phospholipid membranes.

Authors:  Olivier Taboureau; Ole Hvilsted Olsen
Journal:  Eur Biophys J       Date:  2006-11-28       Impact factor: 2.095

8.  In vitro characterization of CT-001-a short-acting factor VIIa with enhanced prohemostatic activity.

Authors:  Derek S Sim; Cornell R Mallari; John M Teare; Richard I Feldman; Maxine Bauzon; Terry W Hermiston
Journal:  Res Pract Thromb Haemost       Date:  2021-06-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.